BCL2 and non-small cell lung carcinoma: The liposomal formulation showed better properties in terms of pathology and the expression of various cancer-related markers such as VEGF, malondialdehyde, TNF-α, caspase-3, and BCL-2 than free curcumin or gemcitabine and hence could be developed further and optimized for intratracheal administration for NSCLC treatment [68].